| Trial ID: | L0934 |
| Source ID: | NCT00784979
|
| Associated Drug: |
Cmvig
|
| Title: |
Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00784979/results
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: CMVIG
|
| Outcome Measures: |
Primary: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor, The percent of sensitized patients treated with PRA Reduction Pharmacological Therapy, including Cytogam, who become cross-match compatible with potential living donor. Treatment success defined as achieving a decrease in donor specific antibody and eliminating cross-match incompatibility sufficient to allow transplantation., four weeks | Secondary: Monitor Graft Survival, 5 years|Monitor Patient Survival, 5 years
|
| Sponsor/Collaborators: |
Sponsor: Tampa General Hospital | Collaborators: CSL Behring
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
26
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-01
|
| Completion Date: |
2012-04
|
| Results First Posted: |
2015-06-29
|
| Last Update Posted: |
2015-06-29
|
| Locations: |
LifeLink HealthCare Institute, Tampa, Florida, 33606, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00784979
|
